Willard Lew

USPTO Granted Patents = 15 (Patent Applications = 8)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 5.6

ph-index = 10

Forward Citations = 206(Granted Patents)

Company Filing History:

13 out of 923

Gilead Sciences, Inc.

patents

2 out of 63

Sunesis Pharmaceuticals, Inc.

patents

Years Active: 1998-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11344565 - Methods for the preparation of ribosides (2022-05-31),

2. 9321753 - [object Object] (2016-04-26),

3. 8884030 - [object Object] (2014-11-11),

4. 8569302 - Inhibitors of flaviviridae viruses (2013-10-29),

5. 8536187 - 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections (2013-09-17),

6. 8524764 - [object Object] (2013-09-03),

7. 8513298 - Inhibitors of flaviviridae viruses (2013-08-20),

8. 7601725 - Thienopyrimidines useful as Aurora kinase inhibitors (2009-10-13),

9. 6878743 - Small molecule inhibitors of caspases (2005-04-12),

10. 6225341 - Compounds and methods for synthesis and therapy (2001-05-01),

11. 6111132 - Compounds and methods for synthesis and therapy (2000-08-29),

12. 5958973 - Polyhydroxy benzoic acid derivatives and their use as neuraminidase (1999-09-28),

13. 5952375 - Compounds and methods for synthesis and therapy (1999-09-14),

14. 5866601 - Carbocyclic compounds (1999-02-02),

15. 5763483 - Carbocyclic compounds (1998-06-09),

Title: Willard Lew: Innovator in Viral Treatment Technologies

Introduction

Willard Lew, an accomplished inventor based in San Mateo, California, has made significant contributions to the medical field, particularly in the development of treatments for viral infections. With a remarkable portfolio of 15 patents, he has focused on innovative methods for synthesizing compounds that hold potential in combating severe viral diseases.

Latest Patents

One of Willard Lew's latest patents revolves around the preparation of ribosides, which provides methods for creating compounds that can be utilized in pharmaceutical compositions aimed at treating Filoviridae virus infections, including Ebola, Marburg, and Cueva virus infections. The synthesis of these compounds involves a complex reaction mixture that incorporates various agents such as magnesium chloride and diisopropylethylamine. Additionally, Lew has developed compounds specifically targeting Flaviviridae virus infections, particularly hepatitis C, further underscoring his expertise in formulating effective antiviral therapies.

Career Highlights

Lew's professional journey includes significant tenures at leading pharmaceutical companies, notably Gilead Sciences, Inc. and Sunesis Pharmaceuticals, Inc. His work in these organizations has been pivotal in advancing viral treatment technologies and enhancing therapeutic approaches to combat infectious diseases.

Collaborations

Throughout his career, Willard has collaborated with notable professionals in the field, including Choung U Kim and Eda Y Canales. These partnerships have contributed to the innovative research and development of his patented methods and compounds, demonstrating the importance of teamwork in scientific advancements.

Conclusion

Willard Lew stands out as a key inventor in the realm of antiviral drug development. His impressive patent portfolio and collaborations reflect his dedication to addressing some of the most pressing viral infections. As he continues to innovate, Lew's contributions undoubtedly have a meaningful impact on public health and therapeutic solutions for viral diseases.

This text is generated by artificial intelligence and may not be accurate.